1. EVALUTE THE EFFICACY OF ADJUVANT REGIMEN 3FEC- 3T IN STAGE II BREAST CANCER
Hai Phong, 2017
LÊ THU HÀ, Ph.D.
Nguyễn Khánh Hà, Dr.

2. Introduction
Breast cancer is the most commonly diagnosed cancer in women
Global (2012): 1,6 million new cases.
Viet Nam (2010): new cases.
Rate of women diagnosed at the early stage (I, II) increases, mortality rate decreases.
Adjuvant chemotherapy, hormone therapy, target therapy are the common ways to treat breast cancer after mastectomy.

3. Introduction
Adjuvant chemotherapy can lower the risk cancer coming back and prolong survival
Regimens in the clinical : AC , CAF , CMF , 4AC – 4T TAC, 3FEC – 3T, 4AC , TC…
Sequencial adjuvant 3FEC – 3T was demonstrated efficacy in breast cancer on the World.
Ha Noi Oncology Hospital started perform 3FEC – 3T in 2010.

4. OBJECTIVE
This study is aim to evaluate the efficacy and the toxicity of 3FEC – 3T regimen in breast cancer patients with stage II after mastectomy.

5. OVERVIEW Diagnosis Stage TNM Multidemensional treatment
Adjuvant chemotherapy
Clinical trials

6. PATIENTS AND METHOD Patients:
Restrospective study of 65 stage II breast cancer patients underwent mastectomy given 3FEC – 3T regimen from 10/2010 to 31/12/2014 at Ha Noi Oncology Hospital.

7. PATIENTS AND METHOD Method: Clinical presentation Staging TNM Surgery
Mortality and morbidity
Toxicity of regimen

8. RESULT AND DISCUSSION
Age
Mean age : 49.8 ±7.926, min: 28, max: 67

9. RESULT AND DISCUSSION
Tumor distance

10. Kết quả và bàn luận
Đặc điểm về di căn hạch

11. RESULT AND DISCUSSION
Pathology

12. RESULT AND DISCUSSION Her2-neu Her-2 Number of patient Rate (%)
Negative 37
56,93
Positive 28
43,07
Total 65
100 

13. RESULT AND DISCUSSION Hormone receptor Feature No. patient Rate (%) ER
Negative 25
38,46
Positive 40
61,54 PR 32
49,23 33
50,77
Total 65
100

14. Time to Median follow – up time : 42,75 ± 13,95 months Max : 78 months
Min : 25 months

15. DFS
DFS 3 years: 78,8%
DFS 5 years: 75,6%

16. OS
OS 3 years: 96,8%
OS 5 years: 94,2%

17. RESULT AND DISCUSSION Clinical Trials PAC-01 GEICAM 9906 TACT We
Roche’ H et al (2006)
Miguel Martín et al (2008)
Ellis P et al (2009)
Clinical Trials
PAC-01
GEICAM 9906
TACT We
DFS (5 năm)
78.4%
78.5%
74,3%
75.6%
OS (5 năm)
90.7% -
94.2%

18. RESULT AND DISCUSSION Phác đồ FAC CMF 3FEC-3T DFS (5 năm) 70.97%
Nguyễn Bá Đức, Trần Văn Thuấn (2002)
Trần Văn Thuấn và cs (2005)
Nguyễn Thị Sang, Trần Thắng, Trần Văn Thuấn, Vũ Hồng Thăng (2014)
Phác đồ
FAC
CMF
3FEC-3T
DFS (5 năm)
70.97%
66.67%
75.6%
OS (5 năm)
80.65%
76.67%
94.2%

19. Correlative between DFS and N

20. Correlative between DFS and HR

21. DFS and other factors
DFS và Her2/neu
DFS và T

22. RESULT AND DISCUSSION
Hematology toxicity

23. Toxicity

24. Toxicity

25. Toxicity Level 1 No. (%) Level 2 Level 3 Level 4 Chán ăn 40 (61,5)
Level 1
No. (%)
Level 2
Level 3
Level 4
Chán ăn
40 (61,5)
5 (7,7)
Anoresia
50 (76,9)
15 (23,1)
Ure/ Creatinin
Cardiology
Neurosensory
27 (41,5)
10 (15,4)

26. Conclusion
DFS and OS improved . DFS after 3 year and 5 year are 78,8%; 75,6% respectivly and OS after 3 year and 5 year are 96,8%; 94,2%.
N (+) lead to decrease survival. DFS and N (+) is 84,7%, DFS and N (-) is 64,7%
DFS and HR (+) is higher than DFS and HR (-) (83,8% và 67,7%)

27. THANKS FOR YOUR ATTENTION